サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566975

ディフェリプロン市場：形態別、用途別、流通チャネル別：世界の機会分析と産業予測、2024～2033年

Deferiprone Market By Form , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
ディフェリプロン市場：形態別、用途別、流通チャネル別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ディフェリプロン市場

ディフェリプロン市場は、2023年に3,340万米ドルと評価され、2024～2033年にかけてCAGR 3.2%で成長し、2033年には4,590万米ドルに達すると予測されています。

デフェリプロンは、輸血や主要サラセミアによる鉄過剰症を治す薬として使用される化合物です。ディフェリプロンの役割は、鉄をキレート化し、尿を通して血流から除去することです。デフェリプロンは錠剤または内服液として摂取され、上部消化管で容易に吸収されます。

デフェリプロン市場の成長は、サラセミアや鎌状赤血球貧血など、定期的な輸血を必要とする疾患の有病率の増加が大きな原動力となっています。さらに、鉄障害に対する意識の高まりが、鉄過剰症に対するデフェリプロンの採用を後押ししています。さらに、数カ国の政府は慢性疾患や鉄関連疾患の治療能力向上に注力しており、これがデフェリプロン需要を高めています。これが市場開拓を後押ししています。現在、市場ではデフェリプロンの用途拡大に関する動向が見られます。American Association for Cancer Research Journalsに掲載された記事によると、デフェリプロンは転移性卵巣がんをコントロールするための代替免疫療法薬として作用すると予想されています。

しかし、デフェリプロンの不適切な投与や過剰投与は、無顆粒球症や好中球減少症などの重篤な副作用を引き起こし、その有用性を制限し、市場の成長を妨げます。さらに、この医薬品はデスフェリオキサミンやデフェラシロックスなど、同等に効率的な代替品との厳しい競合に直面しています。これがデフェリプロン市場の開拓をかなり抑制しています。これとは対照的に、個別化医療の人気の高まりが市場に新たな道をもたらすと予測されています。個別化医療とは、個人の健康状態や体の状態に合わせて薬や治療を提供することです。オーダーメイドの投薬は、人体に副作用を引き起こす可能性がほとんどないため、デフェリプロンの普及を後押しすると予測されます。

セグメント別レビュー

デフェリプロン市場は、形態、用途、流通チャンネル、地域に区分されます。形態別では、市場は錠剤とその他に二分されます。用途別では、輸血性鉄過剰症とNTDTによる鉄過剰症に分けられます。流通チャンネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

形態別では、錠剤セグメントが2023年の市場を独占しました。

用途別では、輸血性鉄過剰症セグメントが2033年までに高い市場シェアを占めると予測されます。

流通チャンネル別では、予測期間を通じてオンラインプロバイダーセグメントが最高株主と予測されます。

地域別では、北米が2023年の市場で最も高い収益を上げました。

本レポートで可能なカスタマイズ（追加費用とスケジュールがあります。）

  • 国、地域、世界レベルでの患者/疫学データ
  • 規制ガイドライン
  • 顧客の関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 デフェリプロン市場：形態別

  • 市場概要
  • 錠剤
  • その他

第5章 デフェリプロン市場：用途別

  • 市場概要
  • 輸血性鉄過剰症
  • NTDTによる鉄過剰症

第6章 デフェリプロン市場：流通チャンネル別

  • 市場概要
  • 病院薬局
  • ドラッグストア
  • オンラインプロバイダー

第7章 デフェリプロン市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のディフェリプロン市場
    • カナダのディフェリプロン市場
    • メキシコのディフェリプロン市場
  • 欧州
    • 主要市場動向と機会
    • フランスのディフェリプロン市場
    • ドイツのディフェリプロン市場
    • イタリアのディフェリプロン市場
    • スペインのディフェリプロン市場
    • 英国のディフェリプロン市場
    • その他の欧州ディフェリプロン市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国のディフェリプロン市場
    • 日本のディフェリプロン市場
    • インドのディフェリプロン市場
    • 韓国のディフェリプロン市場
    • オーストラリアのディフェリプロン市場
    • その他のアジア太平洋のディフェリプロン市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのディフェリプロン市場
    • 南アフリカのディフェリプロン市場
    • サウジアラビアのディフェリプロン市場
    • その他のラテンアメリカ・中東・アフリカのディフェリプロン市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Apotex Inc
  • Cipla Limited
  • VHB Life Sciences Limited
  • Taro Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Chiesi Farmaceutici S.p.A
  • Zydus Cadila
  • Cipla Inc.
  • Pfizer
目次
Product Code: A324401

Deferiprone Market

The deferiprone market was valued at $33.4 million in 2023 and is projected to reach $45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.

Deferiprone is a compound used as a medication for curing iron overload caused by blood transfusions or thalassemia major. The role of deferiprone involves the chelation of iron and its removal from the bloodstream through urine. Deferiprone is consumed as a tablet or oral solution and is readily absorbed by the upper gastrointestinal tract.

The growth of the deferiprone market is significantly driven by increase in the prevalence of diseases that require regular blood transfusions such as thalassemia and sickle cell anemia. In addition, rise in awareness regarding iron disorders is boosting the adoption of deferiprone for iron overload cases. Furthermore, governments in several countries are focusing on the improvement of treatment capabilities for chronic diseases and iron-related disorders, which is upsurging the demand for deferiprone. This is propelling the development of the market. Currently, explorations regarding expansion of the applications of deferiprone are trending in the market. According to an article posted on the American Association for Cancer Research Journals, deferiprone is anticipated to act as an alternative immunotherapeutic drug for the control of metastatic ovarian cancer.

However, improper or excessive dosage of deferiprone leads to severe side effects such as agranulocytosis and neutropenia, limiting its utility and hampering the growth of the market. Furthermore, the medication faces stringent competition from equally efficient alternatives such as desferrioxamine and deferasirox. This restrains the development of the deferiprone market considerably. Contrarily, rise in the popularity of personalized medicine is projected to present new avenues for the market. Personalized medicine involves providing medications and treatments specifically according to an individual's health and body condition. This is projected to boost the uptake of deferiprone as tailored dosages have minimum to no possibility of causing side effects to the human body.

Segment Review

The deferiprone market is segmented into form, application, distribution channel, and region. On the basis of form, the market is bifurcated into tablets and others. As per application, it is divided into transfusional iron overload and NTDT caused overload. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023.

As per application, the transfusional iron overload segment is anticipated to account for a high market share by 2033.

Depending on distribution channel, the online providers segment is projected to be the highest shareholder throughout the forecast period.

Region wise, North America was the highest revenue generator in the market in 2023.

Competition Analysis

The key players operating in the global deferiprone market include Apotex Inc, Cipla Limited, VHB Life Sciences Limited, Taro Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG, Chiesi Farmaceutici S.p.A, Zydus Cadila, Cipla Inc., and Pfizer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Form

  • Tablets
  • Others

By Application

  • Transfusional Iron Overload
  • NTDT Caused Overload.

By Distribution Channel

  • Hospital Pharmacies
  • Drug store retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Apotex Inc
    • Cipla Limited
    • VHB Life Sciences Limited
    • Taro Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis International AG
    • Chiesi Farmaceutici S.p.A
    • Zydus Cadila
    • Cipla Inc.
    • Pfizer

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: DEFERIPRONE MARKET, BY FORM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Form
  • 4.2. Tablets
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Others
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: DEFERIPRONE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Transfusional Iron Overload
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. NTDT Caused Overload.
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Drug Store Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Providers
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: DEFERIPRONE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Form
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Deferiprone Market
      • 7.2.6.1. Market Size and Forecast, By Form
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Deferiprone Market
      • 7.2.7.1. Market Size and Forecast, By Form
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Deferiprone Market
      • 7.2.8.1. Market Size and Forecast, By Form
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Form
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Deferiprone Market
      • 7.3.6.1. Market Size and Forecast, By Form
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Deferiprone Market
      • 7.3.7.1. Market Size and Forecast, By Form
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Deferiprone Market
      • 7.3.8.1. Market Size and Forecast, By Form
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Deferiprone Market
      • 7.3.9.1. Market Size and Forecast, By Form
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Deferiprone Market
      • 7.3.10.1. Market Size and Forecast, By Form
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Deferiprone Market
      • 7.3.11.1. Market Size and Forecast, By Form
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Form
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Deferiprone Market
      • 7.4.6.1. Market Size and Forecast, By Form
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Deferiprone Market
      • 7.4.7.1. Market Size and Forecast, By Form
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Deferiprone Market
      • 7.4.8.1. Market Size and Forecast, By Form
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Deferiprone Market
      • 7.4.9.1. Market Size and Forecast, By Form
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Deferiprone Market
      • 7.4.10.1. Market Size and Forecast, By Form
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Deferiprone Market
      • 7.4.11.1. Market Size and Forecast, By Form
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Form
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Deferiprone Market
      • 7.5.6.1. Market Size and Forecast, By Form
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Deferiprone Market
      • 7.5.7.1. Market Size and Forecast, By Form
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Deferiprone Market
      • 7.5.8.1. Market Size and Forecast, By Form
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Deferiprone Market
      • 7.5.9.1. Market Size and Forecast, By Form
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Apotex Inc
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Cipla Limited
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. VHB Life Sciences Limited
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Taro Pharmaceutical Industries Ltd.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Sun Pharmaceutical Industries Ltd.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Novartis International AG
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Chiesi Farmaceutici S.p.A
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Zydus Cadila
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Cipla Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments